CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30
Cencora, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$340.00−0.92 (-0.27%)
Close on Oct 19, 2026
- Market cap
- $65.94B
- P/E (TTM)
- 25.2
- Dividend yield
- 0.65%
Share price
+$15.31 (+4.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
Cencora, Inc. grew revenue 5.1% to $332.77B over the twelve months to Jun 30, 2026. Operating income rose 11.1% to $3.04B, moving the operating margin from 0.9% to 0.9%. Free cash flow was $4.06B, up 255.7% from a year earlier.
Revenue
$332.77B
+5.1% vs. a year earlier
Operating income
$3.04B
+11.1% vs. a year earlier
Free cash flow
$4.06B
+255.7% vs. a year earlier
EPS, diluted
$13.47
+38.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $65.94B
- P/E ratio
- 25.2
- Price to sales
- 0.20
- Price to book
- 21.61
- Dividend yield
- 0.65%
- Free cash flow yield
- 6.16%
Fundamentals
- Revenue
- $332.77B
- Net income
- $2.62B
- EPS, diluted
- $13.47
- Free cash flow
- $4.06B
- Book value per share
- $15.73
- Diluted shares
- 194M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$332.77B+5.1% YoY
Gross profit
$13.22B+20.0% YoY
Operating income
$3.04B+11.1% YoY
Net income
$2.62B+38.3% YoY
EPS, diluted
$13.47+38.6% YoY
Free cash flow
$4.06B+255.7% YoY
Reported periodTrailing twelve months